Lower response to simeprevir and sofosbuvir in HCV genotype 1 in routine practice compared with clinical trials

BACKGROUND: High sustained virological response at 12 weeks after end of treatment (SVR12) with 12 weeks of simeprevir and sofosbuvir±ribavirin (SMV+SOF±RBV) has been demonstrated in hepatitis C virus genotype 1 (HCV-1) but is based on limited data. Therefore, we performed a meta-analysis of availab...

Descripción completa

Detalles Bibliográficos
Autores principales: Yee, Brittany E, Nguyen, Nghia H, Jin, Minjuan, Lutchman, Glen, Lim, Joseph K, Nguyen, Mindie H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Meta Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4780041/
https://www.ncbi.nlm.nih.gov/pubmed/26966547
http://dx.doi.org/10.1136/bmjgast-2015-000056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4780041/
https://www.ncbi.nlm.nih.gov/pubmed/26966547
http://dx.doi.org/10.1136/bmjgast-2015-000056

Ejemplares similares